The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study

BACKGROUND: Initial studies suggest pharmaceutical grade cannabidiol (CBD) can reduce the frequency of convulsive seizures and lead to improvements in quality of life in children affected by epileptic encephalopathies. With limited access to pharmaceutical CBD, Cannabis extracts in oil are becoming...

Descripción completa

Detalles Bibliográficos
Autores principales: Reithmeier, Darren, Tang-Wai, Richard, Seifert, Blair, Lyon, Andrew W., Alcorn, Jane, Acton, Bryan, Corley, Scott, Prosser-Loose, Erin, Mousseau, Darrell D., Lim, Hyun J., Tellez-Zenteno, Jose, Huh, Linda, Leung, Edward, Carmant, Lionel, Huntsman, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035794/
https://www.ncbi.nlm.nih.gov/pubmed/29981580
http://dx.doi.org/10.1186/s12887-018-1191-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035794/
https://www.ncbi.nlm.nih.gov/pubmed/29981580
http://dx.doi.org/10.1186/s12887-018-1191-y

Ejemplares similares